+

WO1991004052A1 - Vaccins - Google Patents

Vaccins Download PDF

Info

Publication number
WO1991004052A1
WO1991004052A1 PCT/GB1990/001459 GB9001459W WO9104052A1 WO 1991004052 A1 WO1991004052 A1 WO 1991004052A1 GB 9001459 W GB9001459 W GB 9001459W WO 9104052 A1 WO9104052 A1 WO 9104052A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
vaccine according
adjuvant
saponin
antigenic substance
Prior art date
Application number
PCT/GB1990/001459
Other languages
English (en)
Inventor
Bernard Anthony Moss
Roger Aston
William Bulter Cowden
Original Assignee
Peptide Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Technology Ltd. filed Critical Peptide Technology Ltd.
Publication of WO1991004052A1 publication Critical patent/WO1991004052A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Definitions

  • This invention relates to vaccines.
  • Vaccines have classically been used in the prevention of disease.
  • An antigen having antigenic characteristics of a disease-causing entity such as a microbe or toxin
  • a disease-causing entity such as a microbe or toxin
  • the animal's immune system is stimulated to produce antibodies which will react both with the antigen administered and the disease-causing agent itself.
  • vaccines have also been used for other purposes, particularly in the modulation of hormonal activity.
  • Antibodies generated against a hormone antigen may cross react with endogenous hormone in the animal's body.
  • a primary (but not exclusive) application of this new vaccine technology is the production of vaccines for fertility control.
  • antigenicity of many potential antigens is frequently enhanced by the co-application of antigens with immunoadjuvants, which may be regarded as substances which, while not necessarily being antigenic themselves, potentiate or enhance an animal's immune response to the challenging antigen.
  • adjuvants A wide range of adjuvants is known. Examples include Freund's complete and incomplete adjuvants (FCA and FIA) , saponins, aluminium compounds, including aluminium phosphate and aluminium hydroxide (particularly in the form known as alhydrogel) , polycationic electrolytes, polyanionic electrolytes, muramyl dipeptide and Adjuvant 65, which contains highly refined peanut oil and chemically pure mannide monooleate and aluminium monostearate as emulsifier and stabiliser respectively.
  • FCA and FIA Freund's complete and incomplete adjuvants
  • saponins saponins
  • aluminium compounds including aluminium phosphate and aluminium hydroxide (particularly in the form known as alhydrogel)
  • polycationic electrolytes polyanionic electrolytes
  • muramyl dipeptide muramyl dipeptide
  • Adjuvant 65 which contains highly refined peanut oil and chemically pure mannide monooleate and aluminium monostearate as
  • GnRH Gonadotrophin releasing hormone
  • LHRH luteinising hormone releasing hormone
  • GnRH vaccine It is commercially desirable to formulate a GnRH vaccine for veterinary use, particularly but not exclusively for domestic livestock.
  • An antigen GnRH preparation is useful as a fertility regulating or an immunological neutering vaccine in male (for immunocastration) and female (for immunospaying) animals. It is indicative of the difficulties of formulating a GnRH vaccine that the neutering properties of GnRH have been known since 1972, but it is only now that vaccines based on GnRH are beginning to emerge commercially [Hoskinson et al. Aust. J. Biotech, 4, 166-170(1990)]. The utility of a GnRH vaccine is demonstrated by the experiences of Australian stock farmers.
  • GnRH can be formulated as a vaccine with Freund's complete adjuvant (FCA) , which comprises a suspension of heat-killed M. tuberculosis mycobacteria in mineral oil containing a surfactant.
  • FCA Freund's complete adjuvant
  • FCA is recognised as a powerful adjuvant, it has not found wide application outside the laboratory because of the adverse tissue reaction it provokes in recipient animals. In fact, FCA is banned from veterinary use.
  • GnRH vaccine on the market is a two-shot mineral oil based emulsion vaccine in accordance with the teaching of O-A-8801177 [Hoskinson et al. Aust J. Biotech, 4 166-170 (1990)]. Although excellent results can be obtained by the use of such a vaccine, it would be desirable to eliminate the necessity of having oil present, and it would also be desirable to improve the longevity of action of the vaccine so that two shots were not required.
  • the problem with having the mineral oil present is that it can cause localised irritation at the site of injection or implantation, leading among other undesirable effects, to the formation of sterile abscesses and granulomas; further, it is generally desirable to avoid the use of petrochemical-derived materials in preparations administered to animals, particularly parenterally.
  • a vaccine which at least partially solves one or both of the two problems discussed above. Furthermore, it would be preferred if the action of the vaccine was reversible, particularly for a fertility-regulating vaccine such as one based on GnRH, so as to widen the potential market for the vaccine, for example to include horses. Further, it would be preferred if an effective vaccine could be formulated in solid form, which resulted in minimal tissue reaction at the implantation site and which conferred user safety by minimising the possibility of a farmer injecting himself with the formulation and was able to provide improved shelf life stability.
  • a solid vaccine composition comprising an antigenic substance capable of inducing the generation of antibodies on parenteral administration to an animal, a saponin and a polycationic adjuvant.
  • DEAE-dextran is a superior adjuvant to saponin for foot and mouth disease virus.
  • the efficacy of saponin, DEAE-dextran and aluminium hydroxide in a foot and mouth disease vaccine have also been evaluated in pig trials; here, DEAE-dextran performed better than Al(OH) 3 or saponin (Sellers and Herni an Brit. Vet. J. 30 440-445 (1974)) .
  • the short lived nature of the immune response elicited to foot and mouth disease by DEAE-dextran or saponin has been described by Anderson et _____ (Res, in Vet. Sci. 12 351-357 (1971)) .
  • the formulation of these adjuvants into a solid implant vaccine by the particular methods described here provides the basis for veterinary vaccines with longevity.
  • the antigenic substance may give rise to antibodies against a disease-causing agent, or against an agent (such as a hormone) which does not normally give rise to a disease.
  • the disease causing agent may be a structural component or toxin of a virus, bacterium or other microbe.
  • Examples of virally-caused diseases which may be controlled by means of the present invention include foot and mouth disease (FMD) , infectious bursal disease (IBD) , Newcastle disease, rabies, egg drop syndrome virus (EDS 76 ) disease in poultry, calcivirus, rhinotracheitis in cattle, bovine ephemeral fever (BEF) and respiratory virus, among others .
  • Examples of bacterially-caused diseases include botulism, clostridial infections , foot rot ( for a vaccine against which the antigenic substance may comprise Bacterioides nodusus recombinant pili ) , Cas eous Lymphadenitis CLA in sheep caused by Corynebacterium pseudotuberculosis toxin , among others .
  • Other microbial such as fungal or protoz oal , infections may also be controlled by means of the present invention.
  • a vaccine against GnRH is one of the most preferred .
  • Vaccines against other peptide hormones are also commercially signif icant as are vaccines against certain non-peptide hormones , for example steroid hormones .
  • the antigenic substance may consist of the entity against which antibodies are to be raised. This may frequently be the case when the antigenic substance is characteristic of a disease-causing agent.
  • the antigenic substance may comprise a target antigenic moiety conjugated to a carrier.
  • the carrier will generally be selected so as not to be recognised as "self" by the animal to which the vaccine is to be administered.
  • Suitable carriers include albumins including ovalbumin (not for poultry) , bovine serum albumin (not for cattle) , human serum albumin (not for humans) and other albumins.
  • the carrier may be a different protein or other molecule.
  • proteinaceous carriers other than albumin include keyhole limpet haemocyanin and beta-galactosidase, among others. It is not necessary for the carrier either to be a protein or even proteinaceous, but such carriers are preferred. Carriers may in general be available from Sigma, Pierce or Bio Rad, or any other convenient supplier.
  • the implant vaccine described here lends itself to the use of several antigens either linked to the same or different carriers.
  • the implant vaccine may be formulated so that different antigens are presented in distinct implants keeping individual antigens separate.
  • the target antigenic moiety may be conjugated to the carrier, when a carrier is used, by any convenient means. Suitable conjugators include glutaraldehyde, toluene diisocyanate, carbodiimide, or any other suitable conjugator, which may effect a linkage through a carboxyamino group.
  • Such groups may be created by means of activated diacid, such as an acid dichloride or an acid anhydride.
  • Disuccinimidyl compounds are particularly suitable, especially disuccinimidyl tartrate and disuccinimidyl suberate, both of which are available from Pierce, as are many of the other conjugators that are preferred for use in this invention.
  • Other acceptable conjugators effect a linkage through thiol groups as disulphides or thioethers; suitable conjugators include SPDP and other aminodisulphydril cross-linkers and double agents such as MBS.
  • the amount of antigenic substance present in each vaccine dose will of course depend on the identity of the antigenic substance and whether it is conjugated with a carrier. Typically, for a conjugate vaccine it may be expected that the amount of material administered per injection should be from lO ⁇ g to lOmg. For example in a GnRH vaccine, 2mg of conjugates may be present of which 100 to 800 ⁇ g would be GnRH (typically 200 ⁇ g of GnRH) and 1.9 to 1.2mg would be carrier. These amounts are purely illustrative and indicate suitable levels for GnRH vaccines.
  • the saponin may be obtained from any convenient source. Saponin is available from Sigma Chemical Co, USA, and a particularly purified and lyophilised form is available from Superfos Biosector A/S, Denmark, under the trade mark QUIL-A. It should be noted that it is not a prerequsite that a single species be used; mixtures of different saponins are quite acceptable. Preferred saponins include those disclosed in WO-A-8809336.
  • the amount of saponin present can be any appropriate amount. Amounts of from 50 ⁇ g to 50mg may be suitable, for example, from 500 ⁇ g to 5mg; an amount of about lmg may be found to be particularly appropriate.
  • the polycationic adjuvant may be any suitable such adjuvant, particularly including those disclosed in WO-A-8801177. Diethylaminoethyl dextran (DEAE-dextran) is particularly useful and may be supplied as the free base or the hydrochloride or any other appropriate acid addition salt.
  • Diethylaminoethyl dextran (DEAE-dextran) is particularly useful and may be supplied as the free base or the hydrochloride or any other appropriate acid addition salt.
  • Other suitable polycationic adjuvants include polylysine, polyethyleneimine and chitosan, which again may be supplied either as the free base or as an acid addition salt.
  • the polycationic adjuvant may be buffered to be at or near physiological pH, as will subsequently be described.
  • the invention contemplates the use of a conjugate of the antigenic substance and polycationic adjuvant as well as mere mixtures of two separate components.
  • the antigenic moiety and polycationic moiety may therefore be covalently attached, either directly or by means of a linking element.
  • a vaccine in accordance with the invention can optionally contain certain other components.
  • the vaccine may contain a filler.
  • the most preferred filler is calcium phosphate, particularly dibasic calcium phosphate dihydrate.
  • a particularly suitable form of dibasic calcium phosphate dihydrate is sold under the trade mark EMCOMPRESS by Edward Mendel1 Co. Inc., Carmel, New York, USA. This preparation conforms to USP XX/FCC III.
  • the average particle size of the calcium phosphate (or any other filler) may range from 20 to 200 ⁇ m, with 50 to 150 ⁇ m being a typical range. Average particle sizes of about lOO ⁇ m are common.
  • Alternative fillers may also be in the form of biodegradable polymers (see later) .
  • the amount of calcium phosphate or equivalent filler may be such as to adjust the volume of the vaccine composition to a convenient amount. For example, a convenient maximum volume might be 1ml, but the circumstances will vary from case to case.
  • the amount of calcium phosphate (or total filler) per unit dose vaccine formulation may range from lOmg to lg, with from 20mg to 200mg being typical.
  • the filler may comprise from 5 to 95% w/w of the weight of the formulation, with from 30 to 80% w/w being typical.
  • a further filler which may for example be used in conjunction with the preferred calcium phosphate described above, is lactose.
  • a suitable source of anhydrous lactose is direct compression lactose, such as that sold under the trade mark DCLactose 21 by De Melkindustrie Veghel BV of Veghel, The Netherlands. This formulation o —anhydrous lactose satisfies the requirements of USP XXI/NF XVI.
  • the amount of lactose present can vary from 0 to 15% w/w, for example from 5 to 10% w/w, based on the total weight of the vaccine formulation.
  • Another filler which may be used is cholesterol.
  • a suitable source is the USP grade from Croda Inc, USA.
  • the amount of cholesterol present may vary from 0 to 80% w/w, for example from 25 to 50% w/w, based on the total weight of the vaccine formulation.
  • fillers may be present, for *p+91Xexample, sodium calcium hypophosphate or dry (for example freeze dried) aluminium hydroxide may be used as a filler.
  • a lubricant to aid in formulation is desirable.
  • Any suitable lubricant such as magnesium stearate, can be used, but it is generally preferred for the lubricant to comprise a hydrogenated vegetable oil, such as that sold under the trade mark LUBRITAB by Edward Mendell Co, Inc, Carmel, New York, USA.
  • the lubricant may be present in an amount up to 5% w/w, based on the total weight of the vaccine formulation, but is generally present in a range of from 0.5 to 2.5% w/w.
  • adjuvants or components which stimulate the immune response may be present in vaccine formulations in accordance with the invention, if desired.
  • muramyl dipeptide may be present.
  • Lipid-based products may also be present for this purpose.
  • a buffer may be present, for example to counteract the effect that the polycationic adjuvant has on the pH when the vaccine is administered.
  • the vaccines in accordance with the invention are solid and may therefore be in the form of a powder or granules, either of which may optionally be encapsulated, or compressed or otherwise prepared to form a tablet, bolus or extruded strip which may be cut or otherwise post-formed to any convenient length and/or shape.
  • vaccines in accordance with the invention, they will generally be dry. This is not to mean that the vaccine as a whole, or any of the ingredients, is necessarily anhydrous.
  • Vaccines in accordance with the invention may be implantable and/or injectable, and will therefore for preference be sterile.
  • a subcutaneously implantable vaccine is preferred, but an intramuscularly implantable vaccine is also viable.
  • Intraperitoneally implantable vaccines are less preferred but may be suitable in some circumstances. It will not generally be appropriate to implant or inject vaccines in accordance with the invention intravenously, as saponins have a powerful lytic effect on red blood cells.
  • species of animals which can usefully be treated by means of the present invention include cattle, pigs, sheep, deer, camels, horses, dogs and cats, to give but a few examples.
  • the vaccines of the invention can be used for conventional purposes for the treatment of disease.
  • vaccines in accordance with the invention can be used for purposes other than preventing disease, for example for modulating hormone activity, particularly fertility hormone activity.
  • vaccines in accordance with the invention may be used bio-chemically to immunologically neuter bulls and cows. Immunoneutering of sheep and pigs is also a particularly preferred application. Immunocastration of ram lambs destined for the prime lamb market is a specific example.
  • vaccines in accordance with the invention can be restricted to having a single function.
  • Disease-preventing vaccines may be multifunctional, as may hormone activity-modulating vaccines.
  • vaccines in accordance with the invention can combine very different activities, such as disease prevention and hormone activity regulation.
  • Vaccines in accordance with the invention can be prepared by any convenient method, all of which are within the scope of the invention. It may be appropriate under some circumstances to prepare vaccines merely by adequately admixing the ingredients.
  • a process for the preparation of a vaccine comprising admixing (a) an antigenic substance capable of inducing the generation of antibodies on parenteral administration to an animal, (b) a saponin and (c) a polycationic adjuvant.
  • a particularly preferred way to prepare a vaccine in accordance with the first aspect of the invention involves freeze drying the components from a (for example aqueous) solution. For some reason that is not entirely clear, but may be to do with the degree of intimate admixture obtainable by such a process, vaccines prepared in this method have been found to be very satisfactory.
  • a process for the preparation of a vaccine comprising lyophil ising a solution (for example an aqueous solution) of (a) an antigenic substance capable of inducing the generation of antibodies on parenteral administration to an animal , (b) a saponin and (c) a polycationic adjuvant.
  • the solution is preferably stirred thoroughly (for example, for at least 2 hours or even 24 hours or more) prior to lyophilisation for optimum results.
  • the solution will generally be aqueous and may include a buffer to bring the pH of the solution near to neutrality and/or physiological pH.
  • the antigenic substance and the two adjuvants may be preferred to admix the antigenic substance and the two adjuvants with the fillers by wet granulation and lyophilise the common mixture.
  • the antigenic substance and the two adjuvants can be lyophilised from a common solution, it may under some circumstances be possible to prepare satisfactorily an immunoadjuvant composition, to which the antigenic substance can subsequently be added.
  • an immunoadjuvant comprising a saponin and a polycationic adjuvant.
  • vaccines in accordance with the invention are preferably solid.
  • the vaccine may for preference be in tablet form or be formed by extrusion to a desired length.
  • a vaccine including its active components in accordance with the invention may be coated.
  • the coat may be water impermeable but erodible, so that after a suitable period of time the coat will dissolve or otherwise break down to enable release of the active components of the vaccine. It is possible in this way to provide a plurality of implants, ranging from being non-coated to each having a coat of particular thickness and/or erodibility characteristics such that, for example, one implant might release active components immediately to provide a primary sensitising dose while others may release weeks or even months later to provide boosting doses and thereby extend the longevity of the immune response.
  • Polyesters constitute a preferred category of erodible/biodegradable encapsulating polymers that are also biocompatible; examples include polylactide, polyglycolide and poly (lactide-co-glycolide) such as those sold under the trade mark MEDISORB by the Dupont Company, USA., poly(hydroxybutyric acid) such as that sold by Chemie Holding, Linz , Austria, poly(hydroxybutyric acid-co-valeric acid) such as that sold by Aldrich Chemicals, USA, or ICI, UK.
  • erodible biodegradable polymers include polyacetals, polyorthoesters and polyorthocarbonates as is disclosed in EP-A-0052510 (Syntex) . It will be appreciated that coatings can conveniently be made from a mixture of the above or other polymers, particularly when ester derivatives are used.
  • the coat may alternatively remain essentially intact after implantation; it may be semi-permeable to ensure adequate leaching out of ingredient.
  • the coat may be non-biodegradable if desired.
  • Cellulose derivatives constitute a suitable category of polymer; examples include ethyl cellulose, such as that sold under the trade mark ETHOCELL by Dow Chemical Co, USA, methyl cellulose, such as that sold under the trade mark METHOCELL by Dow Chemical Co, USA and hydroxypropylmethyl cellulose, such as that sold under the trade mark PHARMACOAT by Shinetsu Chemical Co of Japan. Methacrylate derivatives form another suitable class.
  • Examples include a 1:2 poly (methacrylic acid, methylmethacrylate) polymer sold under the trade mark EUDRAGIT S100 by Rohm Pharma, West Germany and 1:2:1 poly (butylmethacrylate, methacrylate, methylmethacrylate) polymer sold under the trade mark EUDRAGIT E100 also by Rohm Pharma.
  • the invention in certain circumstances (for example to allow enable pulsed antigen/adjuvant release at delayed time intervals) contemplates coating granules of the active antigen/adjuvant mix itself by solvent evaporation onto granules, wet granulation or fluidised bed spray coating or other means, with a mixture of the above or other erodible or biodegradable polymers prior to formulating into a vaccine as granulates or as compressed tablets.
  • Such polymer coated granules are particularly useful as vaccine implants when used in conjunction with cholesterol as a filler.
  • a method of treating a human or another animal comprising administering a vaccine in accordance with the first aspect of the invention.
  • the invention therefore encompasses the use of (a) an antigenic substance capable of inducing the generation of antibodies on parenteral administration to an animal, (b) a saponin and (c) a polycationic adjuvant in the preparation of a vaccine.
  • vaccines in accordance with the first aspect of the invention can be used as one-shot vaccines, a single shot constitutes the preferred treatment regimen. However, the use of two- and multiple-shots is not ruled out, if the circumstances (or preference) require. If more than one administration is required, the time between administrations is preferably such as to give rise to an effective anamnestic response.
  • lg of GnRH modified at its carboxyl terminus from -gly amide to a -gly acid is added to lg of ovalbumin in water. This is followed by the addition of a 25-fold molar excess over the peptide of l-ethyl-3-(3-dimethyl aminopropyl) carbodiimide hydrochloride, giving a 0.25M solution.
  • the pH of the mixture is controlled at between 6.5 and 7 by titration with 1M hydrochloric acid for at least 5 hours, followed by dialysis against water and then reaction in 0.5M hydroxylamine at pH 7 for 5 hours. The final reaction mix is dialysed against water, filtered through a 0.2 micron membrane and freeze dried.
  • peptide content of the conjugate is determined by differential amino acid analysis relative to the amino acid content of carrier protein alone. (The treatment with hydroxylamine helps obtain a water-soluble product with consistent peptide content.)
  • DEAE-dextran eg from Pharmacia, Sweden, or Sigma Chemical Co, USA
  • saponin eg from Sigma Chemical Co, USA or as a lyophilised preparation such as that sold under the trade mark QUIL-A from Superfos Biosector A/S, Denmark
  • 2g of solid tris-(hydroxymethyl)aminomethane eg Trizma Base Sigma Chemical Co, USA
  • the mixture is dissolved in distilled water (1.75 litres) and adjusted to pH 7 + 0.2 units with a 2M aqueous solution of Trizma (pH 10.5).
  • Antigen peptide-protein conjugate prepared as described above is then added to the neutralised adjuvant solution and dissolved by gentle mixing at ambient temperature (20"C). The solution is stirred thoroughly for at least 24 hours, prior to freeze drying. The dried antigen-adjuvant mix is passed through a stainless steel sieve (350 ⁇ m mesh) prior to tablet preparation.
  • a formulation to make a lOOg powdered mixture for compressing into tablets (implants) is as follows:
  • the batch is prepared— y mixing the calcium phosphate and the lactose together in a tumble mixer at 27rpm for 15 minutes.
  • the antigen/adjuvant mix from Example 1 is then added, and the mixture is blended together for a further 15 minutes in an ERWEKA AR400 (trade mark) cube mixer from Erweka Apparatebau GmbH, Heusenstama, West Germany.
  • the resulting mixture was sieved through a 350 ⁇ m mesh, and the hydrogenated vegetable oil was added to the sieved mixture and then blended for 15 minutes, again in the ERWEKA AR400 cube mixer.
  • the blended mixture of ingredients is compressed into tablets in a 4.5mm punch and dye, using the MANESTY SP1 (trade mark) single punch tabletting machine from Manesty Machines Ltd, Liverpool, UK.
  • the resulting tablets weighed 235mg + 23mg, had a diameter of 4.5mm and a length of 8.6 + 0.6mm.
  • Example 1 The procedure of Example 1 was followed, except that the proportions of the adjuvants, buffer and antigenic conjugate were as follows:
  • the DEAE-dextran, Trizma and Saponin were made up in 350ml distilled water and adjusted to pH 7 with 2M Trizma. A conjugate was then added to this solution, which was thoroughly mixed for 24 hours and then freeze dried. The resulting antigen/adjuvant mix was sieved (350 ⁇ m mesh) , then mixed with the other components in the amounts given below to form implants: EMCOMPRESS Calcium Phosphate 30.31g DC-Lactose 3.37g LUBRITAB hydrogenated vegetable oil 1.04g Antigen/Adjuvant Mix 6.88g
  • This mixture yielded up to 175 implants weighing approximately 235mg each.
  • Each implant contained approximately l.lmg of conjugate, equivalent to about 125 ⁇ g GnRH.
  • Example 3 The tablets produced in Example 3 were used to immunologically castrate rams (Dorset/Merino) as follows.
  • the rams were divided into six groups, each of five animals, and dosed with 1, 2 or 3 tablets in one or two implantations by subcutaneous implantation by means of a trocar in the neck region below the ear.
  • Testicular weight at various time intervals from the first implantation was measured by orchidometry, a comparative palpation procedure using a graded set of beads for reference. [CM. Oldham et al Aust. J. Agric. Res. 29, 173-179 (1978)].
  • the second implantation was 4 weeks after the primary implant.
  • the results eight weeks after the first implantation are shown in Figure 1 and demonstrate the ability of the implant formulation to effect testicular atrophy in mature rams.
  • the implant vaccines were used to examine the effect of changes in immuno-adjuvant formulation on testicular development in growing ram lambs.
  • Groups of 5 second cross ram lambs 5 to 7 weeks of age were immunised subcutaneously in the neck below the ear with various GnRH vaccine implants having varying amounts and treatments of adjuvants.
  • the implants were made as described in Example 3 except that the amounts of DEAE-dextran and/or Saponin were reduced.
  • the amounts of Emcompress calcium phosphate were increased accordingly to maintain implant weights at approximately 235mg.
  • the adjuvants, buffer and antigen conjugates were mixed in aqueous solution for 24 hours prior to freeze drying and incorporation into implants.
  • One implant was given at primary (1°) and one at the secondary (2°) boost 5 weeks later.
  • Table 1 illustrate the effect of varying adjuvant formulation on testicular development in prepubertal ram lambs. Also shown is a dry mixed antigen/adjuvant formulation and a reference oil adjuvant vaccine [Hoskinson et al. Aust. J. BIOTECH 4, 166-170 (1990)] at lmg antigen/2ml dose.
  • CODE Dl
  • SI DEAE-dextran
  • Saponin are in the same amounts as in Example 3.
  • DO SO denotes the absence of DEAE-dextran or Saponin.
  • STD denotes standard formulation as in Example 3.
  • DRY MIX denotes antigen/adjuvant formulation dry mixed only before implant production.
  • Q is Quil A Saponin at half the amount of Sigma Saponin in Example 3 and each implant has 2 mg antigenic conjugate instead of 1.1 mg.
  • VAX is the reference oil adjuvanted vaccine.
  • CONTROLS are placebo implants which contain carbodiimide treated ovalbumin instead of GnRH-ovalbumin conjugate. N.T. denotes not tested.
  • Ram lambs are considered sexually competent when testicular weight exceeds 120 grams (WO-A-8801177) .
  • Table 1 shows that DEAE-dextran and Saponin alone or in combination retard testicular development in lambs when given as adjuvants in GnRH implant vaccines. Combinations of the two adjuvants have a more profound effect. Admixing the adjuvants and antigens in aqueous solution and lyophilising the mixture results in a more effective implant than simple dry admixing (compare groups 1 and 2) . The results demonstrate the viability of solid implant vaccines in immunologically delaying puberty (compare groups 1 and 8 with 10) . The formulation used gives comparable results to a commercial oil-based liquid vaccine (compare groups 1 and 8 with 9) .
  • Example 6 The effect of implant GnRH vaccines (single administration) on testicular status in growing ram lambs or mature rams were examined (Table 2 and Figure 2) .
  • Groups of second cross ram lambs (3 to 5 weeks of age) and mature rams (12 months) were immunised subcutaneously by trocar in the neck region below the ear with GnRH vaccine implants'.
  • the implants were prepared as indicated for Group 8 in Example 5 (Table 1) in which Quil A saponin was used and each implant (235mg size) contained 2 mg of GnRH conjugate.
  • the implants were used uncoated or were coated (lO ⁇ m thick) with an under layer of hydroxypropylmethylcellulose ("Pharmacoat" HPMC 615;Shinetsu Chemical Co Ltd.
  • the implants were pan coated using an Erweka AR 400 drive unit, a 9.5 litre (type DK) coating pan and an Aeromatic (type Strea-1) spraying device with ER 39 nozzle (1.1 mm orifice).
  • CODE QI denotes an implant prepared with Quil A
  • Coated QI denotes that the implant was subsequently coated as described in the text.
  • VAX is the reference oil adjuvant vaccine. Controls are placebo implants as described in Table 2.
  • the mixture was carefully stirred to dissolve the components and the pH was adjusted to 7.0 with 2M Trizma.
  • the solution was stirred for 24 hours at 20°C prior to freeze drying.
  • the dried antigen/adjuvant mix was sieved through a 350 ⁇ m stainless steel mesh.
  • Formulations were made to contain the equivalent of either one dose (A) or about half dose (B) of antigen per implant as follows:
  • Implants were made as described in Examples 2 and 3 and administered via trocar. A single implant was used at each vaccination except where designated as "A+B" in Table 3 below - in these cases the animals were vaccinated both with one A and with one B tablet at the same time at the same site. An oil adjuvanted liquid vaccine in 1ml volume served as a reference standard - this was prepared from the same antigen mix at the dose level of the A implants.
  • Groups of 8 sheep were immunised with a 4 week interdose interval.
  • individual sera were tested for response to each of 5 serogroups (A,B,C,D, and I); results presented below (Table 3) are grand geometric means (GGM) i.e. the mean of the geometric means for the 5 serogroups.
  • GGM grand geometric means
  • Implant A at first dose /Implant A at boost.
  • Standard 1°, 2° Conventional oil vaccine at first dose. Conventional oil vaccine at boost.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions de vaccins sous forme solide comprenant une substance antigène, une saponine et un adjuvant polycationique, par exemple DEAE-dextrane. La substance antigène libère des anticorps à des fins anti-infectieuses ou autres: par exemple les anticorps de la GnRH peuvent moduler la fertilité. L'association d'une saponine et d'un adjuvant polycationique améliore la durée de vie du vaccin et lui permet d'être utilisé comme implant.
PCT/GB1990/001459 1989-09-22 1990-09-21 Vaccins WO1991004052A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898921470A GB8921470D0 (en) 1989-09-22 1989-09-22 Vaccines
GB8921470.4 1989-09-22

Publications (1)

Publication Number Publication Date
WO1991004052A1 true WO1991004052A1 (fr) 1991-04-04

Family

ID=10663489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/001459 WO1991004052A1 (fr) 1989-09-22 1990-09-21 Vaccins

Country Status (5)

Country Link
EP (1) EP0491833A1 (fr)
AU (1) AU640414B2 (fr)
CA (1) CA2066653A1 (fr)
GB (1) GB8921470D0 (fr)
WO (1) WO1991004052A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
WO1999010008A1 (fr) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient
WO1999027959A1 (fr) * 1997-11-28 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Composition a base de saponine, tenant lieu d'adjuvant
WO2000041720A1 (fr) * 1999-01-08 2000-07-20 Csl Limited Compositions adjuvantes ameliorees a base de saponine et procedes en rapport
WO1999062545A3 (fr) * 1998-06-04 2001-03-15 Biostar Inc Procede permettant de supprimer le comportement reproducteur chez les animaux
WO2001024822A3 (fr) * 1999-10-01 2001-12-20 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
WO2002053184A3 (fr) * 2001-01-05 2002-09-19 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Utilisations de composes polycationiques
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US8084015B2 (en) 2002-02-14 2011-12-27 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8552161B2 (en) 2009-02-09 2013-10-08 Uniwersytet W Bialymstoku Saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
RU2730011C2 (ru) * 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
CN112516325A (zh) * 2019-09-18 2021-03-19 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
CN113967252A (zh) * 2020-07-24 2022-01-25 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006129A1 (fr) * 1986-04-10 1987-10-22 Daratech Pty. Ltd. Vaccin et implant
EP0284406A1 (fr) * 1987-03-27 1988-09-28 Pitman-Moore Limited Molécules biologiquement actives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006129A1 (fr) * 1986-04-10 1987-10-22 Daratech Pty. Ltd. Vaccin et implant
EP0284406A1 (fr) * 1987-03-27 1988-09-28 Pitman-Moore Limited Molécules biologiquement actives

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US6132720A (en) * 1994-01-27 2000-10-17 Aphton Corp. Immunogens against gonadotropin releasing hormone
US6303123B1 (en) 1994-01-27 2001-10-16 Aphton Corporation Methods for the treatment of hormone-dependent tumors with immunogens against gonadotropin releasing hormone
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
WO1999010008A1 (fr) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient
US6528058B1 (en) 1997-11-28 2003-03-04 Commonwealth Scientific And Industrial Research Organisation Saponin adjuvant composition
WO1999027959A1 (fr) * 1997-11-28 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Composition a base de saponine, tenant lieu d'adjuvant
WO1999062545A3 (fr) * 1998-06-04 2001-03-15 Biostar Inc Procede permettant de supprimer le comportement reproducteur chez les animaux
EP1946773A3 (fr) * 1999-01-08 2008-07-30 Csl Limited Compositions d'adjuvant de saponine améliorée et procédés associés
WO2000041720A1 (fr) * 1999-01-08 2000-07-20 Csl Limited Compositions adjuvantes ameliorees a base de saponine et procedes en rapport
US9579379B1 (en) * 1999-01-08 2017-02-28 Zoetis Services Llc Saponin adjuvant compositions and methods relating thereto
US9149520B2 (en) 1999-01-08 2015-10-06 Zoetis Services Llc Saponin adjuvant compositions and methods relating thereto
AU758133B2 (en) * 1999-01-08 2003-03-13 Zoetis Services Llc Improved saponin adjuvant composition and methods relating thereto
JP2012072157A (ja) * 1999-01-08 2012-04-12 Pfizer Inc 改良サポニンアジュバント組成物およびそれに関する方法
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1745798A2 (fr) 1999-10-01 2007-01-24 Intercell AG Compositions de vaccin vhc
EP2269642A2 (fr) 1999-10-01 2011-01-05 Intercell AG Compositions de vaccin vhc
EP2269640A2 (fr) 1999-10-01 2011-01-05 Intercell AG Compositions de vaccin vhc
EP2269643A2 (fr) 1999-10-01 2011-01-05 Intercell AG Compositions de vaccin vhc
EP2269641A2 (fr) 1999-10-01 2011-01-05 Intercell AG Compositions de vaccin vhc
WO2001024822A3 (fr) * 1999-10-01 2001-12-20 Cistem Biotechnologies Gmbh Composition pharmaceutique comprenant un antigene
US8277815B2 (en) 1999-10-01 2012-10-02 Intercell Ag Pharmaceutical composition comprising an antigen
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
WO2002053184A3 (fr) * 2001-01-05 2002-09-19 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Utilisations de composes polycationiques
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8084015B2 (en) 2002-02-14 2011-12-27 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8552161B2 (en) 2009-02-09 2013-10-08 Uniwersytet W Bialymstoku Saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
RU2730011C2 (ru) * 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
CN112516325A (zh) * 2019-09-18 2021-03-19 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
CN113967252A (zh) * 2020-07-24 2022-01-25 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
CN113967252B (zh) * 2020-07-24 2024-03-26 洛阳赛威生物科技有限公司 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用

Also Published As

Publication number Publication date
CA2066653A1 (fr) 1991-03-23
AU640414B2 (en) 1993-08-26
EP0491833A1 (fr) 1992-07-01
AU6421090A (en) 1991-04-18
GB8921470D0 (en) 1989-11-08

Similar Documents

Publication Publication Date Title
AU640414B2 (en) Vaccines
AU2003213091B2 (en) Stabilized Synthetic Immunogen Delivery System
Bowersock et al. Vaccine delivery to animals
Esparza et al. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid
EP0724431B1 (fr) Procedes et compositions de microencapsulation d'adjuvants
KR100201352B1 (ko) 단일주사 백신 제형
Igartua et al. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres
CA2180424C (fr) Medicaments, vaccins et hormones incorpores dans des microspheres recouvertes de polylactides
Tobío et al. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle
US5643605A (en) Methods and compositions for microencapsulation of adjuvants
KR100574216B1 (ko) 면역강화 조성물
JP3455226B2 (ja) 抗原、またはアミノ酸配列を含有する化合物のインビボジェネレーターを具備してなる治療用組成物
Payne et al. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery
NZ506975A (en) Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US20040258702A1 (en) Vaccine delivery
US6117432A (en) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
Yeh et al. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination
US6689370B1 (en) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
Wilson Evaluation of the immune response to a tetanus toxoid vaccine using a novel biodegradable polymer adjuvant
AU2006253914A1 (en) Vaccine compositions and methods for the treatment of urinary incontinence
MXPA00008860A (en) Lipophilic microparticles containing a protein drug or antigen and formulation comprising same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2066653

Country of ref document: CA

Ref document number: 1990914402

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990914402

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990914402

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载